932737-65-0 Usage
Description
FITM, also known as 4-Fluoro-N-methyl-N-[4-[6-[(1-methylethyl)amino]-4-pyrimidinyl]-2-thiazolyl]benzamide, is a potent mGluR1 antagonist with potential applications in various fields.
Uses
Used in Pharmaceutical Industry:
FITM is used as an antipsychotic agent for its potent antipsychotic-like effects in several animal models. It is suitable for the development of a PET tracer, which can help in the diagnosis and monitoring of psychiatric disorders.
Used in Research and Development:
FITM is used as a research tool for studying the role of mGluR1 receptors in various physiological and pathological processes. Its potent antagonistic activity allows researchers to investigate the mechanisms underlying the regulation of these receptors and their potential therapeutic applications.
Used in Drug Discovery:
FITM serves as a lead compound for the development of new drugs targeting mGluR1 receptors. Its potent antagonistic activity and selectivity make it an attractive candidate for further optimization and development into more effective and safer therapeutic agents.
Check Digit Verification of cas no
The CAS Registry Mumber 932737-65-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,3,2,7,3 and 7 respectively; the second part has 2 digits, 6 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 932737-65:
(8*9)+(7*3)+(6*2)+(5*7)+(4*3)+(3*7)+(2*6)+(1*5)=190
190 % 10 = 0
So 932737-65-0 is a valid CAS Registry Number.
932737-65-0Relevant articles and documents
Derisking the Cu-Mediated 18F-Fluorination of Heterocyclic Positron Emission Tomography Radioligands
Taylor, Nicholas J.,Emer, Enrico,Preshlock, Sean,Schedler, Michael,Tredwell, Matthew,Verhoog, Stefan,Mercier, Joel,Genicot, Christophe,Gouverneur, Véronique
, p. 8267 - 8276 (2017/06/27)
Molecules labeled with fluorine-18 (18F) are used in positron emission tomography to visualize, characterize and measure biological processes in the body. Despite recent advances in the incorporation of 18F onto arenes, the development of general and efficient approaches to label radioligands necessary for drug discovery programs remains a significant task. This full account describes a derisking approach toward the radiosynthesis of heterocyclic positron emission tomography (PET) radioligands using the copper-mediated 18F-fluorination of aryl boron reagents with 18F-fluoride as a model reaction. This approach is based on a study examining how the presence of heterocycles commonly used in drug development affects the efficiency of 18F-fluorination for a representative aryl boron reagent, and on the labeling of more than 50 (hetero)aryl boronic esters. This set of data allows for the application of this derisking strategy to the successful radiosynthesis of seven structurally complex pharmaceutically relevant heterocycle-containing molecules.
